



Registry Identification Code (RIC):

Participant Details	
Date of Birth:	Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female <input type="checkbox"/> Other <input type="checkbox"/> Uncertain
Ethnicity: White <input type="checkbox"/> English/Welsh/Scottish/Northern Irish/British <input type="checkbox"/> Irish <input type="checkbox"/> Gypsy or Irish Traveller <input type="checkbox"/> Any other White background Mixed/Multiple ethnic groups <input type="checkbox"/> White and Black Caribbean <input type="checkbox"/> White and Black African <input type="checkbox"/> White and Asian <input type="checkbox"/> Any other Mixed/Multiple ethnic background	Asian/Asian British <input type="checkbox"/> Indian <input type="checkbox"/> Pakistani <input type="checkbox"/> Bangladeshi <input type="checkbox"/> Chinese <input type="checkbox"/> Any other Asian background Black/ African/Caribbean/Black British <input type="checkbox"/> African <input type="checkbox"/> Caribbean <input type="checkbox"/> Any other Black/African/Caribbean background Other ethnic group <input type="checkbox"/> Arab <input type="checkbox"/> Any other ethnic group <input type="checkbox"/> Unknown Other, please specify:
Secondary ITP Diagnosis Date:	
Consent date for Secondary ITP Registry:	
Blood Samples	
Has the participant consented to provide biological samples?	
1. Yes 2. No	
Was a biological sample sent?	
1. Yes 2. No	
Sample Sent Date:	
Sample Received Date (Registry Team To Complete):	

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

Secondary/Associated Condition Details. This section is related to the Secondary/Associated Condition.

Secondary ITP Diagnosis Date:

What is the Secondary/Associated Condition the participant has?

- ☐ Connective tissue disorder
- ☐ Malignancy
- ☐ Antiphospholipid Syndrome
- ☐ Infection
- ☐ Immunodeficiency
 - o Specify type: _____
- ☐ Evans Syndrome (ITP + AIHA)
- ☐ ITP associated with autoimmune neutropenia
- ☐ Drug induced
 - o Specify drug name: _____
- ☐ Vaccine Associated ITP. (Please enter the vaccine details in the 'Secondary ITP Vaccination History' Form.
- ☐ Name of vaccine: _____
- ☐ Post transfusion purpura
- ☐ ITP post Haematopoietic Stem Cell Transplant (HSCT)
- ☐ ITP post Solid Organ Transplant
- ☐ Other (please specify) _____

If 'Connective tissue disorder', select type:

- ☐ Systemic Lupus Erythematosus (SLE)
- ☐ Rheumatoid Arthritis
- ☐ Sicca Syndrome
- ☐ Mixed Connective Tissue Disorder
- ☐ Systemic Sclerosis
- ☐ Dermatopolymyositis
- ☐ Other (please specify) _____

Was the associated condition diagnosed prior to the ITP diagnosis?

- ☐ Yes; what previous treatment(s) had the participant received but was no longer on at ITP presentation?
 - o Corticosteroids
 - o Mycophenolate
 - o Azathioprine
 - o Cyclosporin
 - o Cyclophosphamide
 - o Hydroxychloroquine
 - o Methotrexate
 - o Sulfasalazine
 - o Leflunomide
 - o Rituximab (anti-CD20)
 - o Belimumab (BAFF inhibitor)
 - o Infliximab (anti-TNF)
 - o Adalimumab (anti-TNF)
 - o Certolizumab pegol (anti-TNF)
 - o Etanercept (anti-TNF)
 - o Golimumab (anti-TNF)
 - o Brodalumab (anti-IL17)
 - o Guselkumab (anti-IL12)
 - o Ustekinumab (anti-IL12/23)
 - o Mepolizumab (anti-IL5)
 - o Anakinra (anti-IL1)

Formatted

Formatted: Superscript

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

- ☐ Canakinumab (anti-IL1)
- ☐ Tocilizumab (anti-IL6)
- ☐ Sarilumab (anti-IL6)
- ☐ Abatacept (T cell inhibitor)
- ☐ Targeted synthetic DMARDS: tofacitinib (JAK inhibitor)
- ☐ Baricitinib (JAK inhibitor)
- ☐ Filgotinib (JAK inhibitor)
- ☐ Upadacitinib (JAK inhibitor)
- ☐ Other treatment (please specify): _____

☐ No

Was the disease considered otherwise active at ITP presentation? e.g. symptomatic

☐ Yes; what previous treatment(s) had the participant received but was no longer on at ITP presentation?

- ☐ Corticosteroids
- ☐ Mycophenolate
- ☐ Azathioprine
- ☐ Cyclosporin
- ☐ Cyclophosphamide
- ☐ Hydroxychloroquine
- ☐ Methotrexate
- ☐ Sulfasalazine
- ☐ Leflunomide
- ☐ Rituximab (anti-CD20)
- ☐ Belimumab (BAFF inhibitor)
- ☐ Infliximab (anti-TNF)
- ☐ Adalimumab (anti-TNF)
- ☐ Certolizumab pegol (anti-TNF)
- ☐ Etanercept (anti-TNF)
- ☐ Golimumab (anti-TNF)
- ☐ Brodalumab (anti-IL17)
- ☐ Guselkumab (anti-IL12)
- ☐ Ustekinumab (anti-IL12/23)
- ☐ Mepolizumab (anti-IL5)
- ☐ Anakinra (anti-IL1)
- ☐ Canakinumab (anti-IL1)
- ☐ Tocilizumab (anti-IL6)
- ☐ Sarilumab (anti-IL6)
- ☐ Abatacept (T cell inhibitor)
- ☐ Targeted synthetic DMARDS: tofacitinib (JAK inhibitor)
- ☐ Baricitinib (JAK inhibitor)
- ☐ Filgotinib (JAK inhibitor)
- ☐ Upadacitinib (JAK inhibitor)
- ☐ Other treatment (please specify): _____

☐ No

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

If 'Malignancy', select type:

- ☐ Solid organ malignancy.
 - Specify type: _____
- ☐ Clonal paraprotein detected but no overt haematological malignancy
 - (Specify subtype e.g. IgG/Ig M, and diagnosis if known e.g. MGUS):

- ☐ Haematological malignancy (select type)
 - Multiple Myeloma
 - Lymphoma
 - Specify type: _____
 - B-Cell CLL
 - Waldenstrom Macroglobulinaemia (WM)
- ☐ Other
 - Specify type: _____

If 'Solid organ malignancy' for malignancy type, was the associated condition diagnosed prior to the ITP diagnosis?

- ☐ Yes: Initial treatment of malignancy:
 - Surgical resection
 - Radiotherapy
 - Chemotherapy; specify details: _____
 - Adjunctive therapy; specify details: _____
- ☐ No

Subsequent treatment: _____

Disease status at time of ITP presentation:

- ☐ Cured or no known active disease & off treatment (excluding adjunctive therapy)
- ☐ Persisting or recurring local disease
- ☐ Metastatic disease
- ☐ Other, (please specify): _____

Was the participant receiving treatment at time of ITP presentation?

- ☐ Yes (please specify): _____
- ☐ No

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

If 'Clonal paraprotein detected but no overt haematological malignancy', 'Haematological malignancy' or 'Other' for malignancy type, was the associated condition diagnosed prior to the ITP diagnosis?

- ☐ Yes (What previous treatment(s) had the participant received but was no longer on at ITP presentation?): _____
- ☐ No

Was the disease considered otherwise active at ITP presentation? e.g. symptomatic

- ☐ Yes (What treatment(s) was the participant receiving at the time of ITP presentation?): _____
- ☐ No

If 'Antiphospholipid Syndrome'; prior history of thrombosis?

- ☐ Yes (Please enter the thrombosis details in the 'Comorbidities and events of specialist interest' Form.)
- ☐ No

Was the associated condition diagnosed prior to the ITP diagnosis?

- ☐ Yes; what previous treatment(s) had the participant received but was no longer on at ITP presentation? _____
- ☐ No

Was the disease considered otherwise active at ITP presentation? e.g. symptomatic

- ☐ Yes (What treatment(s) was the participant receiving at the time of ITP presentation?): _____
- ☐ No

If 'Infection', select type:

- ☐ HIV
- ☐ Hepatitis C
- ☐ Hepatitis B
- ☐ Transient infection associated with onset of ITP
- ☐ Specify type: _____
- ☐ Other
- ☐ Specify type: _____

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

Was the associated condition diagnosed prior to the ITP diagnosis?

- ☐ Yes; what previous treatment(s) had the participant received but was no longer on at ITP presentation?

- ☐ No

Was the disease considered otherwise active at ITP presentation? e.g. symptomatic

- ☐ Yes (What treatment(s) was the participant receiving at the time of ITP presentation?):

- ☐ No

If 'Immunodeficiency', Vaccine trial response; any relevant genetic test results?

- ☐ Yes (please specify): _____
- ☐ No

Was the associated condition diagnosed prior to the ITP diagnosis?

- ☐ Yes; what previous treatment(s) had the participant received but was no longer on at ITP presentation?

- ☐ No

Was the disease considered otherwise active at ITP presentation? e.g. symptomatic

- ☐ Yes (What treatment(s) was the participant receiving at the time of ITP presentation?):

- ☐ No

For all other remaining Secondary/Associated Conditions (Evans Syndrome (ITP + AIHA); ITP associated with autoimmune neutropenia; Drug induced; Vaccine Associated ITP; Post transfusion purpura; ITP post Haematopoietic Stem Cell Transplant (HSCT); ITP post Solid Organ Transplant; Other):

Was the associated condition diagnosed prior to the ITP diagnosis?

- ☐ Yes; what previous treatment(s) had the participant received but was no longer on at ITP presentation?

- ☐ No

Was the disease considered otherwise active at ITP presentation? e.g. symptomatic

- ☐ Yes (What treatment(s) was the participant receiving at the time of ITP presentation?):

- ☐ No

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

Secondary ITP Vaccination History								
What vaccine did the patient receive?	If COVID-19 vaccine, which vaccine type did the patient receive?	Date of vaccine	Did the patient receive a second vaccine dose?	Which COVID-19 vaccine type did the patient receive?	Date of second vaccine	Did the patient receive a third/booster dose for the COVID-19 vaccine?	Which COVID-19 vaccine type did the patient receive?	Date of third/booster vaccine
COVID-19 vaccine Flu vaccine Hepatitis A vaccine Hepatitis B vaccine Haemophilus influenzae type b (Hib) vaccine Pneumococcal vaccine Meningitis B vaccine Hib/Men C vaccine Meningitis ACWY vaccine Other (please specify) Not known	Pfizer-BioNTech Oxford-AstraZeneca Moderna Other (please specify) Not known		Yes No Uncertain	Pfizer-BioNTech Oxford-AstraZeneca Moderna Other (please specify) Not known		Yes No Uncertain	Pfizer-BioNTech Oxford-AstraZeneca Moderna Other (please specify) Not known	

Formatted Table

Formatted: Superscript

Formatted: Superscript

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

Anthropometric and Lifestyle Data - Please enter the following anthropometric and lifestyle information. Please complete at the time of registration. Repeat entries not required.	
Weight (kg): kg	Height (cm): cm
Month of weight:	Month of height:
Year of weight:	Year of height:
Smoking status at consent: <input type="checkbox"/> No data <input type="checkbox"/> Never smoked <input type="checkbox"/> Ex-smoker <input type="checkbox"/> Current smoker	
Month smoking status was record:	
Year smoking status was record:	
Does the participant drink alcohol? <ul style="list-style-type: none">• Yes• No• No information available	
Alcohol amount: <input type="checkbox"/> Occasional <input type="checkbox"/> <10 units per week <input type="checkbox"/> 11-20 units per week <input type="checkbox"/> 21-40 units per week <input type="checkbox"/> >40 units per week <input type="checkbox"/> Amount not available	
Month drinking status was recorded: Year drinking status was recorded:	

[illegible]Proforma v2.1.0 – 1st August 2023~~Protocol v4.2—15th May~~

Formatted: Superscript

IRAS ID: 92703

[illegible]

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

Organ			
Bleed Site (Select one)	Bleed Type (Select based on bleed site)	Was transfusion required	Date of Bleed
Gastrointestinal bleed (e.g. rectal bleed, haematemesis and malaena) Gynaecological bleed Haemarthrosis Intracranial bleed Intramuscular haematoma Ocular haemorrhage Pulmonary haemorrhage (e.g. haemoptysis, bleed into the lungs) Urinary (haematuria) Other internal bleed (please specify)	GI Bleed type: Occult blood Lower GI bleed Haematemesis and/ or malaena Other (please specify)	Yes No	
	Gynaecological Bleed Type: Occult blood Lower GI bleed Haematemesis and/ or malaena Other (please specify)		
	Intracranial Bleed Type: Traumatic Non-traumatic		
	Ocular Bleed Type: Retinal bleeds Vitreous bleeds Other (please specify)		
	Haematuria Bleed Type: Microscopic Macroscopic		
e.g. Ocular haemorrhage	e.g. Vitreous bleeds	e.g. Yes	e.g. 01/09/2018

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.04.0)

[illegible]Proforma v2.1.0 – ~~1st August~~15th May 2023
2023

IRAS ID: 92703

~~Protocol v4.2 – 15th May~~

Formatted: Superscript

--	--

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

ITP Surgical Treatments

Has the participant been considered for splenectomy or splenic embolization?

- ☐ Yes
☐ No (move onto the next section)

Did the participant have an indium labelled scan?

- ☐ Yes; what was the result:
- ☐ Pure splenic sequestrations
 - ☐ Mixed Sequestrations
 - ☐ Hepatic Sequestration
 - ☐ Inconclusive results
 - ☐ Not stated
- ☐ No

What treatment did the participant have?

- | | |
|---|---|
| <input type="checkbox"/> Splenectomy (specify type): <ul style="list-style-type: none"> <input type="radio"/> Laparoscopic <input type="radio"/> Open <input type="radio"/> Not recorded | <input type="checkbox"/> Splenic embolization |
|---|---|

Procedure date:

Did the participant have additional treatment to elevate the platelet count prior to the procedure?

- ☐ Yes (please enter details in the 'Medical ITP Treatments' form)
☐ No
☐ Uncertain

Were there any post-operative complications?

- ☐ Yes
☐ No
☐ Uncertain

If 'Yes', complication type:

- ☐ Thrombosis
☐ Intra-abdominal abscess
☐ Splenic abscess
☐ Bacterial sepsis
☐ Other (please specify):

Complication Location:

Complication date:

Did the participant receive hyposplenic vaccinations?

- ☐ Yes
- ☐ No
- ☐ Uncertain

Date of hyposplenic vaccination:

Did the participant get started on prophylactic antibiotics?

- ☐ Yes
- ☐ No; why:

○ _____

- ☐ Uncertain

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

ITP Medical Treatments						
Medical ITP Treatments - Please use headings provided in first row to guide completion of remaining rows						
Treatment	Unit of Dose	Dose	Start Date	Is participant still taking this medication ?	If No, end date	How long (days) were steroids prescribed for?
Prednisolone IVIg Dexamethasone Methylprednisolone Mycophenolate Rituximab Romiplostim Eltrombopag Azathioprine Cyclophosphamide Cyclosporine Danazol Dapsone Vinca Alkaloids Anti-D Fostamatinib Avatrombopag Other (please specify)	g g/day g/kg/day mg mg/day mg/week mg/m ² /week mg/alternate days µg/kg/week Oral IV mg OD (once daily) mg BD (twice daily) mg once per week mg twice per week mg three times per week Other					

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-9)

[illegible]

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

Impact of Treatment given for Secondary/Associated condition at or after ITP Presentation

Since the ITP diagnosis, has the participant received treatment/intervention for the secondary disorder?

- ☐ Yes
☐ No (move onto the next section)

Treatment/Intervention:

- ☐ Tumour resection, tumour radiotherapy, tumour chemotherapy
- ☐ Anti-microbial treatment of infection (please specify):

- ☐ Drug cessation (e.g. if drug induced thrombocytopenia) (please specify):

- ☐ Chemotherapy for haematological malignancy (please specify):

- ☐ Immunotherapy for systemic connective tissue disorder (please specify)

- ☐ Switching or reducing immune therapy post solid organ transplantation (please specify drug and what the change was):

- ☐ Immunoglobulin replacement therapy for immunodeficiency disorder
- ☐ HSCT intervention (e.g. DLI, GVHD treatment etc) (please specify)

- ☐ Other (please specify)

Treatment/Intervention start date:

Treatment/Intervention Dose:

Is participant still taking this treatment/intervention?

- ☐ Yes; enter today's date:
☐ No: enter treatment end date:

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

Impact of activity of Secondary/Associated condition on course of ITP. Please use headings provided in first row to guide completion of remaining rows		
Has a progression or relapse of the original associated condition resulted in a relapse of the ITP?	If 'Yes', Describe the relapse/progression of the associated condition:	Relapse/progression date:
<input type="checkbox"/> Yes <input type="checkbox"/> No		
Was there an ITP relapse that was associated with/triggered by a different associated condition?	If 'Yes', what was the associated condition?	Associated condition date:
<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Connective tissue disorder <input type="checkbox"/> Malignancy <input type="checkbox"/> Antiphospholipid Syndrome <input type="checkbox"/> Infection <input type="checkbox"/> Immunodeficiency <input type="checkbox"/> Evans Syndrome (ITP + AIHA) <input type="checkbox"/> ITP associated with autoimmune neutropenia <input type="checkbox"/> Drug induced <input type="checkbox"/> Vaccine Associated ITP <input type="checkbox"/> Post transfusion purpura <input type="checkbox"/> ITP post Haematopoietic Stem Cell Transplant (HSCT) <input type="checkbox"/> ITP post Solid Organ Transplant <input type="checkbox"/> Other (please specify): 	

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

Co-morbidities - Please use headings provided in first row to guide completion of remaining rows

Co-morbidity	Type of Autoimmune disease	Type of Endocrine disorder	Type of Infection	Type of Arterial Thrombosis	Type of Venous Thrombosis	Date of Diagnosis
<ul style="list-style-type: none"> Autoimmune Disease Cataracts Chronic Liver Disease Depression/ Anxiety Endocrine Disorder Hyperlipidaemia/ Hypercholesteraemia Hypertension Infection Renal Failure/Impairment Splenomegaly Thrombosis- Arterial Haemorrhagic Cerebrovascular Accident (Stroke) Thrombosis- Venous Other Bone or Joint Conditions Other Musculoskeletal Conditions Cancer Other (please specify) 	<ul style="list-style-type: none"> Antiphospholipid syndrome (APS) Aplastic anemia Autoimmune hepatitis Crohn's disease Evans syndrome Haemolytic anaemia Pernicious Anaemia Rheumatoid arthritis Systemic lupus erythematosus (SLE) Ulcerative colitis Other (please specify) 	<ul style="list-style-type: none"> Diabetes, Type 1 Diabetes, Type 2 Hyperthyroidism (HYPER-thyroidism) Hypothyroidism (HYPO-thyroidism) Cushing's Syndrome Addison's Disease Other (please specify) 	<ul style="list-style-type: none"> COVID-19 Candida Infection Cytomegalovirus H. Pylori Infection Hepatitis A Hepatitis B Hepatitis C Human Immunodeficiency Virus (HIV) Influenza Measles Mumps Other Respiratory Infection (e.g. Upper Airway Respiratory Infection) Pneumonia (inc. bacterial, viral, fungal or protozoan) Rubella Other (please specify) 	<ul style="list-style-type: none"> Acute Coronary Syndrome/ Myocardial Infarction (ACS) Ischaemic Cerebrovascular Accident (Stroke) Non-cerebral, non-coronary arterial thrombosis (i.e. excludes ACS) Revascularisation Procedure (CABG or PCTA) Stable Angina (SA) Transient Ischaemic Attack (TIA) Other (please specify) 	<ul style="list-style-type: none"> Deep Vein Thrombosis (DVT) Pulmonary Embolism (PE) Portal Vein Thrombosis (PVT) Renal Vein Thrombosis (RVT) Splenic Vein Thrombosis (SpVT) Superficial Vein Thrombosis Other 	

Formatted: Header distance from edge: 1.25 cm, Footer distance from edge: 1.25 cm

Formatted Table

Formatted Table

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

COVID-19 – If Comorbidity was 'Infection' and 'COVID-19' for 'Type of Infection' above.							
What was the maximum level of care required for the patient due to the COVID-19 diagnosis?	Did the patient bleed?	Did the patients platelet count drop?	Did the patient require treatment for COVID-19?	If 'Yes', Name of treatment received for COVID-19 (Select all that apply)	If 'No', Why was the decision taken not to treat?	Did the patient take part in any COVID-19 clinical trial? If 'Yes', please give name of trial.	Is the patient alive?
<ul style="list-style-type: none"> • Outpatient management • Inpatient stay no oxygen • One of: oxygen through CPAP / hi-flow OR cardiovascular support OR renal replacement therapy • Two of: oxygen through CPAP / hi-flow OR cardiovascular support OR renal replacement therapy • Intubation and ventilation • ECMO 	<ul style="list-style-type: none"> • Yes (please enter details in the 'Bleeding events' form) • No • Uncertain 	<ul style="list-style-type: none"> • Yes (please enter platelet count information in the 'Full Blood Counts (Hbs, Neutrophils, Plts)' form) • No • Uncertain 	<ul style="list-style-type: none"> • Yes • No • Uncertain 	<ul style="list-style-type: none"> • Dexamethasone • Low Molecular Weight Heparin • Tocilizumab • Sarilumab • Remdesivir • Treatment for ITP (please enter details in the 'ITP Treatments form') • Other 	<ul style="list-style-type: none"> • Not indicated on basis of platelet nadir • Treatment indicated, but deemed too high risk because of COVID • Treatment indicated, but deemed too high risk because of non-COVID reasons, • Patient choice • Other 		<ul style="list-style-type: none"> • Yes • No • Uncertain

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

Cancer			
Has the participant ever had a malignancy?	If Haematological Malignancy, type	If Solid Tumour, type	Date of diagnosis
<ul style="list-style-type: none"> Haematological Malignancy Solid Tumour 	<ul style="list-style-type: none"> Acute lymphoblastic leukaemia Acute myeloid leukaemia Chronic lymphocytic leukaemia Chronic myeloid leukaemia Chronic myeloproliferative disease Hodgkins lymphoma Multiple myeloma and malignant plasma cell neoplasms Myelodysplastic syndromes Non- Hodgkins lymphoma Waldenstrom's macroglobulinaemia Other (please specify) 	Malignant neoplasm of adrenal gland Malignant neoplasm of anus and anal canal Malignant neoplasm of bladder Malignant neoplasm of bone and articular cartilage of limbs Malignant neoplasm of brain Malignant neoplasm of breast Malignant neoplasm of bronchus and lung Malignant neoplasm of oral cavity or tonsil Malignant neoplasm of cervix uteri Malignant neoplasm of colon Malignant neoplasm of gallbladder Malignant neoplasm of kidney Malignant neoplasm of larynx Malignant neoplasm of liver Malignant neoplasm of oesophagus Malignant neoplasm of ovary Malignant neoplasm of pancreas Malignant neoplasm of prostate Malignant neoplasm of rectum Malignant melanoma of skin Malignant neoplasm of skin- not melanoma Malignant neoplasm of small intestine Malignant neoplasm of stomach Malignant neoplasm of testis Malignant neoplasm of thyroid gland Malignant neoplasm of trachea Malignant neoplasm of uterus Malignant neoplasm of vulva Mesothelioma Malignant neoplasm- no specification of site Other (please specify)	

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

Family History - Please use headings provided in first row to guide completion of remaining rows							
Family History Disease Type	Type of Autoimmune disease	Type of Cancer		Type of Coagulation Disorder	Type of Ischaemic Heart Disease	Type of Stroke	Relationship to participant
<ul style="list-style-type: none"> Autoimmune Disease Cancer Coagulation Disorder Immune Thrombocytopenia (ITP) Ischaemic Heart Disease Stroke Other (please specify) 	<ul style="list-style-type: none"> Antiphospholipid syndrome (APS) Aplastic anemia Autoimmune hepatitis Crohn's disease Evans syndrome Haemolytic anaemia Pernicious Anaemia Rheumatoid arthritis Systemic lupus erythematosus (SLE) Ulcerative colitis Other (please specify) 	Haematological Malignancy	<ul style="list-style-type: none"> Acute lymphoblastic leukaemia Acute myeloid leukaemia Chronic lymphocytic leukaemia Chronic myeloid leukaemia Chronic myeloproliferative disease Hodgkins lymphoma Multiple myeloma and malignant plasma cell neoplasms Myelodysplastic syndromes Non- Hodgkins lymphoma Waldenstrom's macroglobulinaemia Other (please specify) 	<ul style="list-style-type: none"> Deep Vein Thrombosis (DVT) Pulmonary Embolism (PE) Other (please specify) 	<ul style="list-style-type: none"> Acute Coronary Syndrome (ACS) Stable Angina (SA) Revascularisation Procedure (CABG or PCTA) Other (please specify) Unknown 	<ul style="list-style-type: none"> Ischaemic Haemorrhagic Not Known 	<ul style="list-style-type: none"> Mother Father Sister Brother Identical Twin Maternal Grandmother Paternal Grandmother Grandmother (Side unknown) Maternal Grandfather Paternal Grandfather Grandfather (Side unknown) Other (please specify) Unknown
		Solid Tumour	<ul style="list-style-type: none"> Malignant neoplasm of adrenal gland Malignant neoplasm of anus and anal canal Malignant neoplasm of bladder Malignant neoplasm of bone and articular cartilage of limbs Malignant neoplasm of brain 				

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

			<ul style="list-style-type: none"> • Malignant neoplasm of breast • Malignant neoplasm of bronchus and lung • Malignant neoplasm of oral cavity or tonsil • Malignant neoplasm of cervix uteri • Malignant neoplasm of colon • Malignant neoplasm of gallbladder • Malignant neoplasm of kidney • Malignant neoplasm of larynx • Malignant neoplasm of liver • Malignant neoplasm of oesophagus • Malignant neoplasm of ovary • Malignant neoplasm of pancreas • Malignant neoplasm of prostate • Malignant neoplasm of rectum • Malignant melanoma of skin • Malignant neoplasm of skin- not melanoma • Malignant neoplasm of small intestine • Malignant neoplasm of stomach • Malignant neoplasm of testis • Malignant neoplasm of thyroid gland • Malignant neoplasm of trachea • Malignant neoplasm of uterus • Malignant neoplasm of vulva • Mesothelioma • Malignant neoplasm- no specification of site • Other (please specify) 				

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01.0)

UK ADULT ITP REGISTRY- SECONDARY ITP INITIAL INFORMATION SHEET (2.01.0)

Biochemical Test At Diagnosis —Please give these values from time of diagnosis or as close to diagnosis as possible		
Blood Test	Result	Date of Test
Alanine Transaminase (ALT) (U/L)		
Aspartate Transaminase (AST) (U/L):		
Alkaline Phosphatase (ALP) (U/L):		
Total Bilirubin Level (μmol/L):		
Haematological Fields at Diagnosis —Please give these value from time of diagnosis or as close to diagnosis as possible		
Blood Test	Result	Date of Test
Haemoglobin (g/l)		
Neutrophil Count (x10⁹/L):		
White Blood Cells (x10⁹/L):		
Red Blood Cells (x10⁹/L):		
Platelet Count (x10⁹/L):		
Mean Platelet Volume (fl)		
Blood Group: <input type="checkbox"/> O <input type="checkbox"/> AB <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> Unknown/Untested	RhD Status: <input type="checkbox"/> Positive <input type="checkbox"/> Negative <input type="checkbox"/> Untested <input type="checkbox"/> NA	Date:
Immunological Fields At ITP Diagnosis —Please give these value from time of diagnosis or as close to diagnosis as possible		
Blood Test	Result	Date of Test
IgG (mg/dl) Ref range: 639-1349		

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01.0)

IgM (mg/dl) Ref range: 56-352				
IgA (mg/dl) Ref range: 70-312				
Anti-Nuclear Antibodies <input type="checkbox"/> Positive <input type="checkbox"/> Negative <input type="checkbox"/> Untested <input type="checkbox"/> NA				
Did the participant have an 'Antibody screen' done at the time of diagnosis? <input type="checkbox"/> Yes <input type="checkbox"/> No (move to next section)				
Antibody screen	Positive	Negative	Untested	NA
DNA Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Ro AB (60)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Ro AB (52)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-La Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Sm Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Sm/RNP Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-RNP 68 Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Scl-70 Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Jo-1 Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Centromere Ab	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Chromatin Ab	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Ribosomal P Ab	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (~~2.01.0~~)

Antibody Screens Date:				
Did the participant have a subsequent/another 'Antibody screen' done?				
<input type="checkbox"/> Yes <input type="checkbox"/> No (move to next section)				
Antibody screen	Positive	Negative	Untested	NA
DNA Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Ro-AB (60)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Ro-AB (52)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-La Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Sm Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Sm/RNP Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-RNP-68 Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Scl-70 Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Jo-1 Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Centromere Ab	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Chromatin Ab	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti-Ribosomal-P Ab	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Antibody Screens Date:				

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

Biochemical Test At Diagnosis - Please give these values from time of diagnosis or as close to diagnosis as possible		
Blood Test	Result	Date of Test
Alanine Transaminase (ALT) (U/L)		
Aspartate Transaminase (AST) (U/L):		
Alkaline Phosphatase (ALP) (U/L):		
Total Bilirubin Level (μmol/L):		
Haematological Fields at Diagnosis - Please give these value from time of diagnosis or as close to diagnosis as possible		
Blood Test	Result	Date of Test
Haemoglobin (g/l)		
Neutrophil Count (x10⁹/L):		
White Blood Cells (x10⁹/L):		
Red Blood Cells (x10⁹/L):		
Platelet Count (x10⁹/L):		
Mean Platelet Volume (fl)		
Blood Group: <input type="checkbox"/> O <input type="checkbox"/> AB <input type="checkbox"/> A <input type="checkbox"/> B <input type="checkbox"/> Unknown/Untested	RhD Status: <input type="checkbox"/> Positive <input type="checkbox"/> Negative <input type="checkbox"/> Untested <input type="checkbox"/> NA	Date:
Immunological Fields At ITP Diagnosis - Please give these value from time of diagnosis or as close to diagnosis as possible		
Blood Test	Result	Date of Test
IgG (mg/dl) Ref range: 639-1349		
IgM (mg/dl) Ref range: 56-352		
IgA (mg/dl) Ref range: 70-312		
Anti-Nuclear Antibodies <input type="checkbox"/> Positive <input type="checkbox"/> Negative <input type="checkbox"/> Untested <input type="checkbox"/> NA		

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

Did the participant have an 'Antibody screen' done at the time of diagnosis?

☐ Yes

☐ No (move to next section)

Antibody screen	Positive	Negative	Untested	NA
DNA Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Ro AB (60)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Ro AB (52)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti La Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Sm Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Sm/RNP Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti RNP 68 Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Scl-70 Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Jo-1 Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Centromere Ab	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Chromatin Ab	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Ribosomal P Ab	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Antibody Screens Date:

Did the participant have a subsequent/another 'Antibody screen' done?

☐ Yes

☐ No (move to next section)

Antibody screen	Positive	Negative	Untested	NA
DNA Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Ro AB (60)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Ro AB (52)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti La Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Sm Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Sm/RNP Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti RNP 68 Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Scl-70 Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Jo-1 Antibody	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Centromere Ab	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Chromatin Ab	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anti Ribosomal P Ab	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Antibody Screens Date:

Formatted: Font color: Auto

Formatted: Tab stops: 2.33 cm, Left

Formatted: Superscript

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (2.01-0)

Coagulation Fields At ITP Diagnosis - Please give these value from time of diagnosis or as close to diagnosis as possible

Prothrombin Time (PT):

PT Reference Value:

PT Ratio (INR)

Date:

Activated Partial Thromboplastin Time (APTT):

APTT Ratio:

Date:

Other Tests

Test	Value/Result	Date
Reticulocyte Count		
Reticulocyte Percentage		
Lupus Anticoagulant (LA) <input type="checkbox"/> Positive <input type="checkbox"/> Negative <input type="checkbox"/> Untested <input type="checkbox"/> NA		
Anticardiolipin Antibody- IgG <input type="checkbox"/> Positive <input type="checkbox"/> Negative <input type="checkbox"/> Untested <input type="checkbox"/> NA		
Anticardiolipin Antibody- IgM <input type="checkbox"/> Positive <input type="checkbox"/> Negative <input type="checkbox"/> Untested <input type="checkbox"/> NA		
Anti-Beta-2-Glycoprotein 1 Antibodies (IgG) <input type="checkbox"/> Positive <input type="checkbox"/> Negative <input type="checkbox"/> Untested <input type="checkbox"/> NA		
Anti-Beta-2-Glycoprotein 1 Antibodies (IgM) <input type="checkbox"/> Positive <input type="checkbox"/> Negative <input type="checkbox"/> Untested <input type="checkbox"/> NA		

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (~~2.01.0~~)[illegible]Proforma v2.4.0 – ~~1st August~~15th May 2023
2023~~Protocol v4.2 – 15th May~~

IRAS ID: 92703

Formatted: Tab stops: 2.62 cm, Left

Formatted: Superscript

UK ADULT ITP REGISTRY: SECONDARY ITP INITIAL INFORMATION SHEET (~~2.01.0~~)[illegible]

